MCID: OVR056
MIFTS: 31

Ovarian Primitive Germ Cell Tumor

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Primitive Germ Cell Tumor

MalaCards integrated aliases for Ovarian Primitive Germ Cell Tumor:

Name: Ovarian Primitive Germ Cell Tumor 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5351
NCIt 47 C39986
UMLS 69 C1518727

Summaries for Ovarian Primitive Germ Cell Tumor

MalaCards based summary : Ovarian Primitive Germ Cell Tumor is related to clear cell variant infiltrating bladder urothelial carcinoma and polymyositis. An important gene associated with Ovarian Primitive Germ Cell Tumor is AFP (Alpha Fetoprotein), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Ran Pathway. The drugs Cisplatin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and breast, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and digestive/alimentary

Related Diseases for Ovarian Primitive Germ Cell Tumor

Diseases related to Ovarian Primitive Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
id Related Disease Score Top Affiliating Genes
1 clear cell variant infiltrating bladder urothelial carcinoma 10.7 AFP SERPINA1
2 polymyositis 10.7 AFP SERPINA1
3 mature teratoma 10.7 AFP SALL4
4 mediastinal mesenchymal tumor 10.7 AFP GPC3
5 visual cortex disease 10.7 AFP GPC3
6 diabetes mellitus, insulin-dependent, 20 10.6 AFP GPC3
7 rete ovarii cystadenofibroma 10.6 AFP SERPINA1
8 ovarian mucinous cystadenocarcinoma 10.5 GPC3 SALL4
9 testicular thecoma 10.5 SRY TEK
10 eccrine acrospiroma 10.5 AFP KRT7
11 testicular malignant germ cell cancer 10.5 SRY TEK
12 sex differentiation disease 10.5 AFP SALL4 SERPINA1
13 clear cell squamous cell skin carcinoma 10.5 AFP KRT7
14 tricuspid valve insufficiency 10.5 AFP SERPINA1
15 testicular trophoblastic tumor 10.4 AFP KRT7
16 breast secretory carcinoma 10.4 AFP KRT7
17 testicular germ cell cancer 10.4 AFP KRT7
18 anterolateral myocardial infarction 10.4 AFP SALL4
19 malignant peritoneal solitary fibrous tumor 10.4 AFP KRT7
20 orbital granuloma 10.2 MSX2 SALL4
21 lymphedema 10.2 AFP GPC3 SERPINA1
22 cerebellar vermis medulloblastoma 10.2 AFP GPC3 KRT7
23 ectodermal dysplasia with natal teeth, turnpenny type 10.2 AFP GPC3 KRT7
24 apocrine adenocarcinoma 10.2 AFP GPC3 KRT7
25 gallbladder cancer 10.2 AFP GPC3 KRT7
26 sleep disorder 10.2 AFP GPC3 SALL4 SERPINA1
27 skin tag 10.2 AFP GPC3 KRT7
28 kidney clear cell sarcoma 10.1 EZH2 KRT7
29 superior mesenteric artery syndrome 10.1 KRT7 SRY
30 group b strep disease in newborns 10.1 KRT7 SERPINA1
31 status asthmaticus 9.9 GPC3 SERPINA1
32 uterine corpus apoplectic leiomyoma 9.9 EZH2 KRT7
33 germ cells tumors 9.9
34 mediastinum synovial sarcoma 9.8 AFP KRT7 SERPINA1 SRY
35 hyperbiliverdinemia 9.8 GPC3 KRT7 SRY
36 focal epithelial hyperplasia 5.7 AFP EZH2 GPC3 GSTA1 HLX HOXB7
37 pulmonary coin lesion 5.0 AFP EZH2 GPC3 GSTA1 HLX HOXB7

Graphical network of the top 20 diseases related to Ovarian Primitive Germ Cell Tumor:



Diseases related to Ovarian Primitive Germ Cell Tumor

Symptoms & Phenotypes for Ovarian Primitive Germ Cell Tumor

GenomeRNAi Phenotypes related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.36 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 9.36 SRY
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.36 NKX2-5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.36 SRY
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.36 NKX2-5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.36 AFP NKX2-5 SRY
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.36 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.36 AFP
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.36 AFP

MGI Mouse Phenotypes related to Ovarian Primitive Germ Cell Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.73 GPC3 HLX MSX2 NKX2-5 SALL4 SIRT1
2 embryo MP:0005380 9.7 EZH2 GPC3 MSX2 NKX2-5 SALL4 SIRT1
3 endocrine/exocrine gland MP:0005379 9.56 AFP EZH2 HLX HOXB7 KPNA1 MSX2
4 hematopoietic system MP:0005397 9.28 EZH2 GPC3 HLX HOXB7 KPNA1 MSX2

Drugs & Therapeutics for Ovarian Primitive Germ Cell Tumor

Drugs for Ovarian Primitive Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
5
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
6
Norgestimate Approved Phase 3 35189-28-7 6540478
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Liver Extracts Phase 3,Phase 2,Phase 1
11 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
12 Anti-Bacterial Agents Phase 3,Phase 1
13 Antidotes Phase 3
14 Anti-Infective Agents Phase 3,Phase 2,Phase 1
15 Antioxidants Phase 3
16 Antitubercular Agents Phase 3
17 Chelating Agents Phase 3
18 Protective Agents Phase 3,Phase 2,Phase 1
19 sodium thiosulfate Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Analgesics Phase 3
22 Analgesics, Opioid Phase 3
23 Anesthetics Phase 3
24 Anesthetics, General Phase 3
25 Anesthetics, Intravenous Phase 3
26 Central Nervous System Depressants Phase 3,Phase 2
27 Narcotics Phase 3
28 Peripheral Nervous System Agents Phase 3,Phase 2
29 Antipruritics Phase 3,Phase 2
30 Dermatologic Agents Phase 3,Phase 2
31 Gastrointestinal Agents Phase 3,Phase 2
32 Neurotransmitter Agents Phase 3,Phase 2
33
Serotonin Phase 3,Phase 2 50-67-9 5202
34 Serotonin Agents Phase 3,Phase 2
35 Serotonin Antagonists Phase 3,Phase 2
36 Contraceptive Agents Phase 3
37 Contraceptives, Oral Phase 3
38 Contraceptives, Oral, Combined Phase 3
39 Estradiol 17 beta-cypionate Phase 3
40 Estradiol 3-benzoate Phase 3
41 Estradiol valerate Phase 3 979-32-8
42 Fluoroquinolones Phase 3
43 Norgestimate, ethinyl estradiol drug combination Phase 3
44 Nucleic Acid Synthesis Inhibitors Phase 3
45 Polyestradiol phosphate Phase 3
46 Anti-Allergic Agents Phase 3
47 Histamine Antagonists Phase 3
48 Histamine H1 Antagonists Phase 3
49
Histamine Phosphate Phase 3 51-74-1 65513
50 Cola Nutraceutical Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 53)

id Name Status NCT ID Phase Drugs
1 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
4 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
7 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
8 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
9 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
10 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
11 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
12 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
13 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
14 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
15 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
16 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
17 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
18 Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
19 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
20 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
21 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
22 Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant Withdrawn NCT00728585 Phase 2
23 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
24 ABT-751 in Treating Young Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
25 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
26 Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy Completed NCT00030108 Phase 1 ixabepilone
27 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Completed NCT00020150 Phase 1 O6-benzylguanine;temozolomide
28 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
29 Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors Completed NCT00003107 Phase 1
30 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
31 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
32 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer Completed NCT00060372 Phase 1 ipilimumab;therapeutic allogeneic lymphocytes
33 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
34 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1 cefepime hydrochloride
35 Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1 carboplatin;etoposide;ifosfamide
36 Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
37 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
38 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
39 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
40 Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma Completed NCT00040911
41 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
42 Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed NCT00293384 Aprepitant;Cyclophosphamide;Dexamethasone;Granisetron hydrochloride
43 Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients Completed NCT00082654
44 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed NCT00408681 lithium carbonate
45 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383
46 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
47 Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Active, not recruiting NCT00638898 busulfan;melphalan;topotecan hydrochloride
48 T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Suspended NCT00651716
49 Blood Samples From Patients on a Clinical Trial to CINV During HSCT Terminated NCT00900068
50 Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome Terminated NCT00946283

Search NIH Clinical Center for Ovarian Primitive Germ Cell Tumor

Genetic Tests for Ovarian Primitive Germ Cell Tumor

Anatomical Context for Ovarian Primitive Germ Cell Tumor

MalaCards organs/tissues related to Ovarian Primitive Germ Cell Tumor:

39
Bone, Bone Marrow, Breast, Liver, Colon, T Cells, Brain

Publications for Ovarian Primitive Germ Cell Tumor

Articles related to Ovarian Primitive Germ Cell Tumor:

id Title Authors Year
1
SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. ( 19295406 )
2009

Variations for Ovarian Primitive Germ Cell Tumor

Expression for Ovarian Primitive Germ Cell Tumor

Search GEO for disease gene expression data for Ovarian Primitive Germ Cell Tumor.

Pathways for Ovarian Primitive Germ Cell Tumor

Pathways related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.26 AFP NKX2-5 SERPINA1
2 9.8 KPNA1 KPNA2

GO Terms for Ovarian Primitive Germ Cell Tumor

Cellular components related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ESC/E(Z) complex GO:0035098 8.62 EZH2 SIRT1

Biological processes related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.78 KPNA1 KPNA2 KRT7 SIRT1
2 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.77 EZH2 MSX2 NKX2-5 SALL4 SIRT1
3 embryonic hindlimb morphogenesis GO:0035116 9.46 GPC3 MSX2
4 outflow tract septum morphogenesis GO:0003148 9.43 MSX2 NKX2-5
5 NLS-bearing protein import into nucleus GO:0006607 9.32 KPNA1 KPNA2
6 heart trabecula formation GO:0060347 9.26 NKX2-5 TEK
7 ovulation from ovarian follicle GO:0001542 9.16 AFP SIRT1
8 modulation by virus of host process GO:0019054 8.96 KPNA1 KPNA2
9 regulation of DNA recombination GO:0000018 8.62 KPNA1 KPNA2
10 regulation of transcription, DNA-templated GO:0006355 10.01 EZH2 HLX HOXB7 MSX2 NKX2-5 SALL4

Molecular functions related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.43 EZH2 HLX HOXB7 MSX2 NKX2-5 SALL4
2 nuclear localization sequence binding GO:0008139 9.26 KPNA1 KPNA2
3 transcription factor binding GO:0008134 9.02 MSX2 NKX2-5 SALL4 SIRT1 SRY
4 protein binding GO:0005515 10 AFP EZH2 GPC3 HLX HOXB7 KPNA1

Sources for Ovarian Primitive Germ Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....